Editorial: More Conflicts Come to Light at Stem Cell Institute
By Editorial,
The Sacramento Bee
| 05. 25. 2013
With a new chairman, Jonathan Thomas, the California Institute for Regenerative Medicine claims it has turned a page. Thomas has vowed to be aggressive in avoiding conflicts in dispersing millions of public dollars for stem cell research.
Yet serious conflicts continue to be revealed involving CIRM. The latest one throws into question a $20 million grant awarded last year to StemCells Inc., a company that wants to transplant neural stem cells to treat Alzheimer's disease.
The institute's oversight board approved the award in September, following a lobbying effort by Robert Klein, a former chairman of the oversight board who authored Proposition 71, the initiative that created the stem cell institute. As part of that effort, Klein last year donated $21,000 to CIRM so it could send six of its in-house science officers to a conference in Japan, where Klein had special access to them.
Prior to this lobbying campaign, the institute's outside scientific reviewers recommended twice against awarding the money to StemCells Inc. Yet following Klein's efforts, the oversight board overruled them, agreeing on a 7-5 vote to approve the...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...